Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00881530 · ClinicalTrials.gov registry record · Phase 2
Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 660
- Enrollment target
NCT00881530 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 660 participants.
The verdict
NCT00881530, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 660 participants
- Enrollment target
Study Summary
The objective of the current study is to investigate the safety and efficacy of BI 10773 in 2 different doses compared to Metformin or to Sitagliptin given for 78 weeks in different modalities of treatment in patients with type 2 diabetes mellitus.
Interventions
- DRUG Metformin
- DRUG Sitagliptin
- DRUG BI 10773
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 660 participants |
| Start Date | 2009-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00881530
The ClinicalTrials.gov registry entry for NCT00881530 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 660 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Metformin is the first listed.
NCT00881530 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00881530 about?
NCT00881530 is a clinical study titled "Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension". The objective of the current study is to investigate the safety and efficacy of BI 10773 in 2 different doses compared to Metformin or to Sitagliptin given for 78 weeks in different modalities of treatment in patients with type 2 diabetes mellitus.
What is the current status of trial NCT00881530?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 660 participants. The study started on 2009-03.
What interventions are being tested in trial NCT00881530?
The interventions under investigation include: Metformin (DRUG), Sitagliptin (DRUG), BI 10773 (DRUG).
Who is sponsoring clinical trial NCT00881530?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.